12/12/2025
A step in the right direction💙💙
A meaningful milestone for the Alexander Disease community.
Ionis has received U.S. FDA Breakthrough Therapy Designation for zilganersen for AxD, an important recognition designed to accelerate the development and review of therapies with the potential to offer substantial improvement for serious or life-threatening conditions.
This designation does not mean approval, but it does mean momentum.
Read the full announcement here:
🔗 https://ir.ionis.com/news-releases/news-release-details/ionis-receives-us-fda-breakthrough-therapy-designation
End AxD will continue accelerating research, strengthening advocacy, and ensuring the AxD community remains at the heart of every advancement.